Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of ALD-101 Adjuvant Therapy with Unrelated Umbilical Cord Blood Transplantation in Inborn Errors of Metabolism
2009-011921-15Phase 3Withdrawn
- Sponsor
- Aldagen
- Start
- Apr 2009
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, single-arm trial of ALD-101 in Congenital Metabolic Diseases, sponsored by Aldagen. Primary endpoint: Time to platelet engraftment. Planned start Apr 2009; status: withdrawn.
02
Drugs
ALD-101
03
Conditions
Congenital Metabolic Diseases
Beyond the preview
Go deeper on 2009-011921-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011921-15.